Churchill China
AVOIDAs foreshadowed at its May AGM, ceramics maker Churchill China, which has been hit by a sharp rise in energy prices and slowdown on the UK high street, posted a hefty drop in profits for the half to June. On lower sales of £22.3m (£23.7m), pre-tax profits slipped from £1.3m to £600,000, pulling earnings per share down from 8.7p to 4p. The interim dividend was held at 3.7p. Stephen Roper, chairman, said sales to retail customers failed to hit targets in an ultra-competitive market. Sales to retail customers dropped from £11.4m to £9.8m, with gloom on the UK high street and poor performances in the USA and Europe affecting sales. Roper says the sourcing of products from overseas has reduced costs and made Churchill more competitive. There was a stronger performance in the hospitality business, despite flat demand in most major markets. The premium Alchemy brand of fine china, which is sold to four- and five-star hotels, continued to perform well, with like-for-like sales rocketing up by 65%. Here, Roper insists, there are opportunities to grow sales through new product development of add-on ranges. Cost cutting, together with stronger profit and cash generation in the traditionally busier second half augur well for the latter half-year, which benefits from the run up to Christmas. However, Roper remains cautious on trading, says there’s less consumer spending on eating out, and points out that Churchill China also has to contend with higher gas and pension costs. Management is to be applauded, but there are more compelling stocks around at present. Avoid.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £18.97m
PE Forecast: n/a
Share price: 176.5p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
The Capital Pub Company 31/08/2010
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.
Sectors
